NBY novabay.com: חובות לטווח קצר של החברה

NovaBay Pharmaceuticals (NBY) faces risks associated with declining margins for ophthalmology products and debt leverage, as evidenced by the shift in short-term liabilities on the GURU.Markets daily price chart, where the indicator stands at -0.02. Business stability relies on demand within the pharmacy segment, while management optimization and strict cost controls help minimize current operational threats.

Investors must weigh the growth potential of NovaBay Pharmaceuticals (NBY) against liquidity risks to avoid pitfalls in short-term planning. Monitoring current debt allows for an assessment of obligations maturing within one year, where a stable trend confirms the financial resilience of NovaBay Pharmaceuticals, supported by patent-protected chemical formulas and stable distribution channels within the pharmacy sector.